[Human papillomavirus and cervical cancer: presence and future of vaccination].
The very close relation between human papillomavirus (HPV) and cervical cancer is evident. A vaccine has been awaited for a longtime. After excellent results of phase II trials, a large worldwide phase III trial on a vaccine against HPV of high (types 16, 18) and low malignant potential (types 6, 11) is ongoing. If the vaccine is effective, registered and launched, at least three decades will pass until the incidence of invasive cervical cancer will drop significantly. The prevalence of premalignant lesions and genital warts may be reduced earlier. As, due to the high number of different oncogenic HPV types, complete prevention can hardly be achieved, screening will be necessary in the future. The screening intervals have to be redefined since the risk will decrease.
Joura
Elmar A
EA
Abteilung für Gynäkologie und gynäkologische Onkologie, Universitätsklinik für Frauenheilkunde, Wien, Osterreich. elmar.joura@meuniwien.ac.at
D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003218:Condylomata Acuminata / Q000276:immunology / Q000517:prevention & control; D005260:Female; D005544:Forecasting; D006801:Humans; D008297:Male; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D011230:Precancerous Conditions / Q000276:immunology / Q000517:prevention & control*; D012307:Risk Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control*; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use*
D014765:Viral Vaccines